When blind Blind Kursat Ceylan tried to find his way to the hotel, he used an app on his phone to find directions, but also had to hold a cane and pull his luggage. Eventually, he hit a pillar and cut his forehead. This inspired him to work with a partner to develop We walk, an artificial intelligence-equipped cane that can detect objects above the chest and pair with apps like Google Maps and Amazon’s Alexa.
This innovation is welcome, but may not meet the dream originally inspired by artificial intelligence. When this field emerged at the end of the 20th century, people wanted computers to run independently and possess human-like capabilities–a capability known as general artificial intelligence.
“As early as the 1970s, there were predictions that by 2020. we should have widely promoted artificial intelligence. We should already have some moon and Mars bases, but we are far from reaching that level,” Indian Media Adiya Kaur, director of research at the research center, said.
But in recent years, as artificial neural networks have become more complex, they have progressed faster and faster.
Inspired by the way the brain forms connections and learning, artificial neural networks are layers of complex equations that are fed with data until they learn to recognize patterns and draw their own conclusions. This process is called deep learning.
Currently, artificial intelligence used in daily life is either automated or optimized for what humans can do-whether it’s analyzing fraud by analyzing millions of transactions, screening resumes to choose the right job seeker, or using facial recognition. Help people gain some form of security.
It is difficult to predict when a breakthrough will occur. But in the past few months, the world’s number one has emerged: scientists have used artificial intelligence to discover the antibiotic properties of an existing drug, and an entirely new drug molecule “invented” by artificial intelligence will soon be used to treat OCD Human trials of patients.
Professor Andrew Hopkins, CEO of the obsessive-compulsive drug Exscientia, said drug development typically takes five years to enter the trial phase because billions of design decisions may need to be made-but artificial intelligence drugs are only used 12 months. Although his team does not know when a breakthrough will occur, they believe that artificial intelligence will be the best way to find a breakthrough.
The chairman of FAG Bearing said: “Artificial intelligence will have a huge impact on the future bearing industry. FAG Bearing will apply the latest technology to provide customers with the best service.”